Literature DB >> 3943270

Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines.

A Lelo, J O Miners, R Robson, D J Birkett.   

Abstract

The caffeine content of all tea or coffee beverages consumed by 17 healthy adults over 24 hours was measured. Plasma caffeine, theophylline, theobromine, and paraxanthine concentrations were determined over the same 24 hours. The average caffeine content per drink was 60.4 +/- 21.8 mg for instant coffee (14-fold range), 80.1 +/- 19.2 mg for brewed coffee (2.8-fold range), and 28.8 +/- 13.7 mg for tea (5.5-fold range). The number of drinks of coffee and tea consumed was a poor index of actual caffeine intake (r2 = 0.42). Caffeine intake correlated poorly with the 24-hour average caffeine concentration (r2 = 0.41), but there was a very good correlation between a single plasma caffeine concentration measured at 5 PM and the 24-hour average concentration (r2 = 0.94). The same was true for paraxanthine (r2 = 0.86). Paraxanthine accounted for 67.3% of the total dimethylxanthines in plasma, while theobromine and theophylline accounted for 24.4% and 8.3%, respectively. Mean caffeine clearance was 1.2 +/- 0.3 ml/min/kg. Plasma caffeine concentration before the first drink in the morning correlated very poorly with caffeine clearance (r2 = 0.07), even when adjusted for caffeine intake (r2 = 0.21).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3943270     DOI: 10.1038/clpt.1986.10

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  38 in total

1.  Cortisol responses to mental stress, exercise, and meals following caffeine intake in men and women.

Authors:  William R Lovallo; Noha H Farag; Andrea S Vincent; Terrie L Thomas; Michael F Wilson
Journal:  Pharmacol Biochem Behav       Date:  2006-05-02       Impact factor: 3.533

2.  Effects of caffeine on performance and mood: withdrawal reversal is the most plausible explanation.

Authors:  Jack E James; Peter J Rogers
Journal:  Psychopharmacology (Berl)       Date:  2005-07-02       Impact factor: 4.530

3.  Caffeine stimulation of cortisol secretion across the waking hours in relation to caffeine intake levels.

Authors:  William R Lovallo; Thomas L Whitsett; Mustafa al'Absi; Bong Hee Sung; Andrea S Vincent; Michael F Wilson
Journal:  Psychosom Med       Date:  2005 Sep-Oct       Impact factor: 4.312

4.  Biotransformation of caffeine by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; S Krahenbuhl; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

5.  Effects of caffeine and its metabolite paraxanthine on intracranial self-stimulation in male rats.

Authors:  Matthew F Lazenka; F Gerard Moeller; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2015-04       Impact factor: 3.157

6.  Biochemical validation of self-reported caffeine consumption during caffeine fading.

Authors:  J E James; I Paull; E Cameron-Traub; J O Miners; A Lelo; D J Birkett
Journal:  J Behav Med       Date:  1988-02

7.  Reinforcing and subjective effects of caffeine in normal human volunteers.

Authors:  K N Stern; L D Chait; C E Johanson
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.

Authors:  Charlotte E Edling; Federico Selvaggi; Ragheda Ghonaim; Tania Maffucci; Marco Falasca
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

9.  Caffeine reduces TNFalpha up-regulation in human adipose tissue primary culture.

Authors:  C Dray; D Daviaud; C Guigné; P Valet; I Castan-Laurell
Journal:  J Physiol Biochem       Date:  2007-12       Impact factor: 4.158

10.  Maternal caffeine consumption and risk of neural tube defects.

Authors:  Rebecca J Schmidt; Paul A Romitti; Trudy L Burns; Marilyn L Browne; Charlotte M Druschel; Richard S Olney
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2009-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.